A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...
Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...
A new drug called amycretin is stepping into the spotlight, boasting impressive results that have both researchers and those ...
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...
Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its ...
Novo Nordisk announced Phase 2a trial results for monlunabant. The trial demonstrated a weight reduction of 7.1 kg with a 10 ...
Altimmune (ALT) stock gains as company's obesity candidate pemvidutide shows promise in preserving lean mass in a mid-stage ...
In the study, overweight or obese patients without diabetes received increasing doses of amycretin, starting from 3 milligrams and up to a final dose of two 50 mg pills, Novo said. Patients who ...
In the study, overweight or obese patients without diabetes received increasing doses of amycretin, starting from 3 milligrams and up to a final dose of two 50 mg pills, Novo said. Patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback